Strong Financial Performance
Total revenues and NOI for Q3 2024 were up 10.9% and 12.5%, respectively, over Q3 2023. FFO per share diluted was $2.37, up 4.9% over Q3 2023.
Leasing and Occupancy Success
Leasing volume for Q3 2024 was 1.5 million square feet, up 48% over the trailing 4-quarter average. Occupancy was solid at 94.7%, up 10 basis points over the prior quarter.
Robust Life Science Industry Impact
Since 2013, there have been 519 novel medicines approved by the FDA, with 257 developed or commercialized by Alexandria tenants.
Balance Sheet Strength
Strong balance sheet with $5.4 billion in liquidity and a weighted average remaining term of debt of 12.6 years.
Successful Asset Sales
Completed over $390 million in asset sales in Q3 2024. Expecting to complete $1.2 billion in pending dispositions.